Investors think there's still room to run for Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), which saw its valuation more than double last week on positive Phase II data for a drug combination that could treat nearly half of the cystic fibrosis population.

Shares soared $24.61 (66%) to $62.02 on interim data for the company's VX-809 plus its Kalydeco ivacaftor to treat patients with two copies